Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 796 across all filing types
Latest filing 2025-06-24 Foreign Filer Report
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2025-06-24 English
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
Earnings Release Classification · 1% confidence The document is a press release issued by Pharming Group N.V. on June 24, 2025. It announces a webcast to discuss new research published in the medical journal *Cell* regarding the functional classification of genetic variants related to APDS. The text focuses on scientific findings, clinical implications, and an upcoming investor/analyst event (webcast). This structure—announcing a significant development (research publication) and scheduling an event to discuss it—is characteristic of an Earnings Release (ER) or a general corporate/investor update. Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a formal proxy/dividend notice, and it is specifically focused on communicating recent, material, non-financial news to investors and the media, it best fits the 'Earnings Release' category, which often encompasses major operational or scientific announcements that impact investor perception, even if not strictly quarterly earnings figures. Given the focus on a scientific breakthrough and the announcement of a related webcast, ER is the most appropriate fit among the provided options for a material, time-sensitive announcement. FY 2024
2025-06-24 Dutch
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
Regulatory Filings Classification · 1% confidence The document is a press release titled "Pharming Group to host webcast on findings of a new study published in *Cell*...". It announces an upcoming webcast event (June 30, 2025) to discuss scientific study findings related to APDS diagnosis and features commentary from the Chief Medical Officer and a collaborating researcher. This structure—announcing a future event to discuss results or strategy, often including quotes and background information—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since the primary focus is announcing a specific event (a webcast) to discuss scientific/clinical progress rather than releasing periodic financial results (like quarterly earnings), and it is not a transcript, presentation, or formal regulatory filing like a 10-K, the most fitting category is Earnings Release (ER), as these announcements often accompany or precede financial updates, or it could be classified as Regulatory Filings (RNS) if it were purely scientific. However, given the context of hosting a webcast for investors/analysts to discuss study findings, it functions similarly to an Earnings Release in terms of investor communication cadence, though it is not strictly financial results. Since the document is a detailed press release announcing a specific event and scientific update, and it is not a short announcement pointing to an attached report (ruling out RPA), it is best classified as an Earnings Release (ER) as it serves as a primary communication vehicle for material company news to investors, even if the core topic is scientific advancement rather than quarterly numbers. If a more specific 'Clinical Update' category existed, that would be ideal, but among the given options, ER is the closest fit for a major investor-facing announcement of this nature.
2025-06-24 English
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
AGM Information Classification · 1% confidence The document title explicitly states "Pharming Group publiceert uitkomsten jaarlijkse Algemene Vergadering van Aandeelhouders 2025" (Pharming Group publishes results of the Annual General Meeting of Shareholders 2025). The text details the outcomes of the meeting, including the appointment and re-election of board members and the approval of various proposals. This directly corresponds to the definition of AGM Information (AGM-R). Although it announces the results, the content is substantial enough to be classified as the AGM material itself, rather than just a brief announcement of publication (RPA/RNS).
2025-06-12 Dutch
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
AGM Information Classification · 1% confidence The document explicitly states it reports on the 'results of the 2025 Annual General Meeting of Shareholders (AGM)'. It details board appointments, re-elections, auditor reappointment, and shareholder approvals of various proposals. This content directly aligns with the description of AGM materials, specifically the results and outcomes of the meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document is not a full 10-K, an earnings release (ER), or a proxy statement (PSI), but a summary of the meeting's outcome.
2025-06-12 English
6-K
Foreign Filer Report
2025-06-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.